# ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

> **NCT05501769** · PHASE1 · COMPLETED · sponsor: **Arvinas Estrogen Receptor, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** ARV-471 in combination with Everolimus

## Key facts

- **NCT ID:** NCT05501769
- **Lead sponsor:** Arvinas Estrogen Receptor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-08
- **Primary completion:** 2024-07-03
- **Final completion:** 2025-08-25
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2025-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05501769

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05501769, "ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05501769. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*